Stroke prevention in Atrial Fibrillation


Stroke prevention is the cornerstone of the management of atrial fibrillation (AF), and effective stroke prevention means oral anticoagulation (OAC), irrespective of symptoms or whether a rate or rhythm control approach is employed.1 Whilst the Vitamin K antagonists (VKA, e.g. warfarin) remains widely used worldwide, the landscape of stroke prevention has changed markedly in recent years, with the availability of the non-Vitamin K antagonist oral anticoagulants, the novel oral anticoagulants (NOACs), with increasing ‘real world’ data supporting their use in everyday clinical practice.2–4

Read More

Eur Heart J. 2017 Jan 1;38(1):4-5.